Montpellier, France, February 2, 2016 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce continued commercial expansion with two new sales of its ROSA™ Brain robot in the U.S., to Brigham and Women's Hospital and the University of Colorado Hospital, a member of UCHealth.
Brigham and Women's Hospital, located in Boston, Massachusetts, is one of America's most prestigious hospital centers, and has been recognized as one of the 10 best American hospitals by U.S. News & World Report.
The University of Colorado Hospital, a member of UCHealth in Aurora, Colorado is a renowned institution, particularly for neurology and neurosurgery. In 2015, it was ranked as a best hospital in the state of Colorado by U.S. News & World Report.
Bertin Nahum, CEO and Founder of Medtech, commented, “We are delighted with the ongoing increase of ROSA™ robots sold in the U.S., which is a significant market for our Company. These sales to prestigious institutions demonstrate the growing interest in our ROSA™ technology and the important role it can play supporting leading neurosurgeons and their patients.”
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
Tel : +33 (0)1 53 67 36 77
Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
Joanna Zimmerman (US)
Tel : +1 646-536-7006
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|MEDTECH||Euronext Paris||50.00 (c)||0.00%||0|